Drug Topics Hospital Pharmacists' Report

October 4, 2012

Web Version  |   Unsubscribe  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

TOP STORY

Pertussis vaccine protection wanes

The acellular pertussis vaccine that was introduced in the 1990s may not offer long-lasting protection against whooping cough in immunized children after the fifth dose, according to a case-control study published September 13 in the New England Journal of Medicine. » More

Continuing Education

New CPE Series: MTM in Patients with Diabetes

Welcome to a new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. This month, the professional development activity will cover the pathophysiology, diagnosis, screening, and risk factors associated with diabetes mellitus.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

TODAY'S HEADLINES

Meth, heroin users face dental disease risks

Long-term users of methamphetamine compared with heroin users in an urban setting had a high prevalence of dental disease, much higher than the general U.S. population, according to a small cross-sectional study published Sept. 1 in the Journal of the American Dental Association. » More

Glucocorticoid inhalers may impact adult height

Children with asthma who use glucocorticoid inhalers may grow shorter on average than those who do not use inhaled corticosteroids (ICS), according to a study published September 6 in the New England Journal of Medicine. » More

Biologics for RA treatment don't increase cancer risk

Biologic response modifiers developed for the treatment of rheumatoid arthritis do not appear to be associated with an increased risk of cancer, according to a study published September 5 in the Journal of the American Medical Association.
» More

Apixaban has lower stroke rates compared to warfarin

Apixaban (Eliquis), an investigational anticoagulant developed by Bristol-Myers Squibb and Pfizer, has lower rates of stroke, systemic embolism, and bleeding than warfarin in patients with atrial fibrillation, regardless of level of risk for these events, according a recent online analysis published October 2 in The Lancet. » More

Survey

Has your institution decided to be part of an accountable care organization?

1. Yes, we have established an ACO as of July 1, 2012.

2. Yes, we have applied for ACO status.

3. Yes, but we have not yet applied for ACO status.

4. No, we have no plans to apply for ACO status.


Respond here and see what your colleagues think too.

Want to see the results of our last survey about who your colleagues are voting for in the upcoming election? Click here.


 

Subscribe Now!

You must click here to continue receiving the Drug Topics Hospital Pharmacists' Report

Check these out, too

It's American Pharmacists Month

New online tool available for Janssen products

FDA approves regorafenib for colorectal cancer

FDA: New antibacterial drug development task force

Voices

Anticoagulation Update

JP at Large: Over the line

View from the Zoo: A pharmacy parable

Viewpoints: Guest columnists' commentary

Regulatory and Legal: News, features, analysis

Meetings and Events

 
Powered by Modern Medicine Advanstar Medical Communications Group